Hepatitis B virus (HBV) has been associated with the development of non-Hodgkin lymphoma (NHL) and can be reactivated in patients being treated for NHL.
Methods
Articles published between 2000 and 2015 that discussed an association between NHL and HBV, mechanisms of HBV induction of NHL, and HBV reactivation in patients with NHL were reviewed and the results compiled to help health care professionals better understand the risk of developing NHL in HBV-seropositive individuals, describe potential etiologies by which HBV infection may lead to lymphomagenesis, and highlight the recent medical literature with respect to the reactivation of HBV in the setting of NHL.
Results
An association exists between HBV infection and NHL development. Immunosuppression due to HBV, chronic viral stimulation, and dysregulation of the immune system are possible ways in which lymphoma can develop in patients with HBV infection. All patients being treated with anti-CD20 antibodies or those from or living in HBV-endemic regions should be tested for hepatitis B surface antigen, core antibody, and surface antibody prior to initiating therapy. HBV DNA polymerase chain reaction (PCR) may also be useful in certain cases. Among HBV-seropositive patients or those with detectable HBV DNA, prophylaxis with an antiviral agent should be initiated for 1 year after NHL therapy. HBV DNA PCR monitoring should be undertaken each month during the course of treatment and every 3 months after treatment for a 1-year duration.
Conclusions
Health care professionals should become more comfortable treating these high-risk patients with NHL as they become more informed about potential lymphomagenesis and the reactivation of HBV.
zur HausenH.. Viruses in human cancers.Science.1991; 254(5035): 1167–1173.
4.
MüllerA.M., IhorstG., MertelsmannR.. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology.Ann Hematol.2005; 84(1): 1–12.
5.
HjalgrimH., EngelsE.A.. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence.J Intern Med.2008; 264(6): 537–548.
6.
EngelsE.A.. Infectious agents as causes of non-Hodgkin lymphoma.Cancer Epidemiol Biomarkers Prev.2007; 16(3): 401–404
7.
BassigB.A., LanQ., RothmanN.. Current understanding of lifestyle and environmental factors and risk of non-Hodgkin lymphoma: an epidemiological update.J Cancer Epidemiol.2012; 2012: 978930.
8.
MatsuoK., KusanoA., SugumarA.. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies.Cancer Sci.2004; 95(9): 745–752.
9.
DaliaS., ChavezJ., CastilloJ.J.. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies.Leuk Res.2013; 37(9): 1107–1115.
10.
Dal MasoL., FranceschiS.. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies.Cancer Epidemiol Biomarkers Prev.2006; 15(11): 2078–2085.
LimS.T., FeiG., QuekR.. The relationship of hepatitis B virus infection and non-Hodgkin's lymphoma and its impact on clinical characteristics and prognosis.Eur J Haematol.2007; 79(2): 132–137.
13.
World Health Organization.Hepatitis B vaccines.Weekly Epidemiological Record. 2009; 84(40): 405–420. http://www.who.int/wer/2009/wer8440.pdf. Accessed March 20, 2015.
14.
NathA., AgarwalR., MalhotraP.. Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis.Int Med J.2010; 40(9): 633–641.
15.
ProbyC., MinelloA., QuantinC.. Chronic viral hepatitis and risk of lymphoid malignancies: a retrospective twelve-year population-based cohort study in Côte d'Or, France.Dig Liver Dis.2012; 44(2): 160–165.
16.
BeckerN.. Epidemiology of multiple myeloma.Recent Results Cancer Res.2011; 183: 25–35.
17.
QiuM.Z., RuanD.Y., WangZ.Q.. The expression of hepatitis B virus surface antigen in 120 Hodgkin's lymphoma patients.Chin J Cancer.2010; 29(8): 735–740.
18.
AndersonL.A., PfeifferR., WarrenJ.L.. Hematopoietic malignancies associated with viral and alcoholic hepatitis.Cancer Epidemiol Biomarkers Prev.2008; 17(11): 3069–3075.
19.
CucuianuA., PatiuM., DumaM.. Hepatitis B and C virus infection in Romanian non-Hodgkin's lymphoma patients.Br J Hematol.1999; 107(2): 353–356.
20.
KumagaiK., TakagiT., NakamuraS.. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan.Ann Oncol.1997; 8(Suppl 1): 107–109.
21.
KimJ.H., BangY.J., ParkB.J.. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study.Jpn J Cancer Res.2002; 93(5): 471–477.
22.
FwuC.W., ChienY.C., YouS.L.. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan.Hepatology.2011; 53(4): 1217–1225.
23.
BeckerN., SchnitzlerP., BoffettaP.. Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case-control study Epilymph.J Cancer Res Clin Oncol.2012; 138(12): 1993–2001.
24.
EngelsE.A., ChoE.R., JeeS.H.. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study.Lancet Oncol.2010; 11(9): 827–834.
25.
GalunE., IlanY., LivniN.. Hepatitis B virus infection associated with hematopoietic tumors.Am J Pathol. 1994.1994; 145(5): 1001–1007.
26.
BeckerN., BylA., FriedrichS.. Hepatitis B virus infection is associated with deletion of chromosome 8p in multiple myeloma.Eur J Haematol.2013; 90(4): 279–285.
27.
LiJ., LiuJ., HuangB.. Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation.Tumour Biol.2013; 34(3): 1723–1728.
28.
MehdiS.R., Al AjlanA.R.. Hepatitis B&C virus infection in cases of non-Hodgkin's lymphoma in Saudi Arabia.Turk J Hematol.2006; 23(4): 200–204.
29.
MarcucciF., MeleA.. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities.Blood.2011; 117(6): 1792–1798.
30.
WangF., XuR.H., HanB.. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers.Cancer.2007; 109(7): 1360–1364.
31.
IwataH., MatsuoK., TakeuchiK.. High incidences of malignant lymphoma in patients infected with hepatitis B or hepatitis C virus.Haematologica.2004; 89(3): 368–370.
32.
KangJ., ChoJ.H., SuhC.W.. High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies.Ann Hematol.2011; 90(2): 159–164.
33.
MarcucciF., MeleA., SpadaE.. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma.Haematologica.2006; 91(4): 554–557.
34.
ParkS.C., JeongS.H., KimJ.. High prevalence of hepatitis B virus infection in patients with B-cell non-Hodgkin's lymphoma in Korea.J Med Virol.2008; 80(6): 960–966.
35.
ChenM.H., HsiaoL.T., ChiouT.J.. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin's lymphoma.Ann Hematol.2008; 87(6): 475–480.
36.
VladareanuA.M., CiufuC., NeaguA.M.. The impact of hepatitis viruses on chronic lymphoproliferative disorders; preliminary results.J Med Life.2010; 3(3): 320–329.
37.
FranceschiS., LiseM., TrépoC.. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC).Cancer Epidemiol Biomarkers Prev.2011; 20(1): 208–214.
38.
IdilmanR., BozkusY., SevalG.. Lymphoproliferative disorders in individuals with chronic hepatitis B and C in the Turkish population.J Med Virol.2011; 83(6): 974–980.
39.
BeckerN., FortunyJ., AlvaroT.. Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH).J Cancer Res Clin Oncol.2009; 135(8): 1099–1107.
40.
MolagicV., AramaV., CercelA.S.. Preliminary data on the involvement of B, C and D hepatitis viruses in the etiopathogenesis of chronic lymphoproliferative syndromes in Romania.Rom J Intern Med.2009; 47(1): 25–34.
41.
OkanV., YilmazM., BayramA.. Prevalence of hepatitis B and C viruses in patients with lymphoproliferative disorders.Int J Hematol.2008; 88(4): 403–408.
42.
KuniyoshiM., NakamutaM., SakaiH.. Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin's lymphoma.J Gastroenterol Hepatol.2001; 16(2): 215–219.
43.
SonmezM., BektasO., YilmazM.. The relation of lymphoma and hepatitis B virus/hepatitis C virus infections in the region of East Black Sea, Turkey.Tumori.2007; 93(6): 536–539.
44.
El-SayedG.M., MohamedW.S., NouhM.A.. Viral genomes and antigen detection of hepatitis B and C viruses in involved lymph nodes of Egyptian non-Hodgkin's lymphoma patients.Egypt J Immunol.2006; 13(1): 105–114.
45.
FisherS.G., FisherR.I.. The epidemiology of non-Hodgkin's lymphoma.Oncogene.2004; 23(38): 6524–6534.
TirelliU., SpinaM., GaidanoG.. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active anti-retroviral therapy.Aids.2000; 14(12): 1675–1688.
48.
YoffeB., NoonanC.A., MelnickJ.L.. Hepatitis B virus DNA in mononuclear cells and analysis of cell subsets for the presence of replicative intermediates of viral DNA.J Infect Dis.1986; 153(3): 471–477.
49.
ViswanathaD.S., DoganA.. Hepatitis C virus and lymphoma.J Clin Pathol.2007; 60(12): 1378–1383.
50.
BouvardV., BaanR., StraifK.. A review of human carcinogens. Part B: biological agents.Lancet Oncol.2009; 10(4): 321–322.
51.
TalamoT.S., DekkerA., GureckiJ.. Primary hepatic malignant lymphoma: its occurrence in a patient with chronic active hepatitis, cirrhosis, and hepatocellular carcinoma associated with hepatitis B viral infection.Cancer.1980; 46(2): 336–339.
52.
DewantoroO., GaniR.A., AkbarN.. Hepatocarcinogenesis in viral Hepatitis B infection: the role of HBx and p53.Acta Med Indones.2006; 38(3): 154–159.
53.
LeungN.. HBV and liver cancer.Med J Malaysia.2005; 60(suppl B): 63–66.
54.
WangX.W., ForresterK., YehH.. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3.Proc Natl Acad Sci U S A.1994; 91(6): 2230–2234.
55.
ChanC., WangY., ChowP.K.. Altered binding site selection of p53 transcription cassettes by hepatitis B virus X protein.Mol Cell Biol.2013; 33(3): 485–97.
56.
AlexanderD.D., MinkP.J., AdamiH.O.. The non-Hodgkin lymphomas: a review of the epidemiologic literature.Int J Cancer.2007; 120(Suppl 12): 1–39.
57.
LokA.S., LiangR.H., ChiuE.K.. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.Gastroenterology.1991; 100(1): 182–188.
58.
LauG.K.. Hepatitis B reactivation after chemotherapy: two decades of clinical research.Hepatol Int.2008; 2(2): 152–162.
59.
RiedellP., CarsonK.R.. A drug safety evaluation of rituximab and risk of hepatitis B.Expert Opin Drug Saf.2014; 13(7): 977–987.
60.
MitkaM.. FDA: Increased HBV reactivation risk with ofatumumab or rituximab.JAMA.2013; 310(16): 1664.
61.
YangJ.D., GirotraM., VaidA.. Hepatitis B reactivation in patient with non-Hodgkin's lymphoma receiving rituximab-based chemotherapy: need for education and attention.J Ark Med Soc.2013; 110(6): 110–112.
62.
TsutsumiY., YamamotoY., ShimonoJ.. Hepatitis B virus reactivation with rituximab-containing regimen.World J Hepatol.2013; 5(11): 612–620.
63.
MatsuiT., KangJ.H., NojimaM.. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma.J Med Virol.2013; 85(11): 1900–1906.
64.
KimS.J., HsuC., SongY.Q.. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.Eur J Cancer.2013; 49(16): 3486–3496.
65.
DongH.J., NiL.N., ShengG.F.. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis.J Clin Virol.2013; 57(3): 209–214.
66.
EvensA.M., JovanovicB.D., SuY.C.. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.Ann Oncol.2011; 22(5): 1170–1180.
67.
NiitsuN., HagiwaraY., TanaeK.. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.J Clin Oncol.2010; 28(34): 5097–5100.
68.
MatsueK., KimuraS., TakanashiY.. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.Cancer.2010; 116(20): 4769–4776.
69.
LawJ.K., HoJ.K., HoskinsP.J.. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations.Leuk Lymphoma.2005; 46(7): 1085–1089.
70.
HoofnagleJ.H.. Reactivation of hepatitis B.Hepatology.2009; 49 (5 suppl): S156–S165.
GuptaS., GovindarajanS., FongT-L,. Spontaneous reactivation in chronic hepatitis B: patterns and natural history.J Clin Gastroenterol.1990; 12(5): 562–568.
73.
YeoW., ChanP.K., ZhongS.. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.J Med Virol.2000; 62(3): 299–307.
74.
LiangR.. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation.Blood.2009; 113(14): 3147–3153.
75.
NakamuraY., MotokuraT., FujitaA.. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.Cancer.1996; 78(10): 2210–2215.
76.
VassiliadisT., GaripidouV., TziomalosK.. Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy: a prospective case series.Am J Hematol.2005; 80(3): 197–203.
77.
BréchotC., DegosF., LugassyC.. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen.N Engl J Med.1985; 312(5): 270–276.
78.
TarghettaC., CabrasM.G., MamusaA.M.. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy.Haematologica.2008; 93(6): 951–952.
79.
KusumotoS., TobinaiK.. Screening for and management of hepatitis B virus reactivation in patients treated with anti-B-cell therapy.Hematology Am Soc Hematol Educ Program.2014; 2014(1): 576–583.
80.
ArnoldD.M., CrowtherM.A., MeyerR.M.. Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia.Transfusion.2010; 50(12): 2577–2581.
81.
HayA.E., MeyerR.M.. Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness.J Clin Oncol.2012; 30(26): 3155–3157.
82.
ZurawskaU., HicksL.K., WooG.. Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis.J Clin Oncol.2012; 30(26): 3167–3173.
LauG.K., YiuH.H., FongD.Y.. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.Gastroenterology.2003; 125(6): 1742–1749.
85.
WangY.H., FanL., WangL.. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy.Support Care Cancer.2013; 21(5): 1265–1271.
86.
ChenX.Q., PengJ.W., LinG.N.. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.Med Oncol.2012; 29(2): 1237–1241.
87.
KimY.M., JeongS.H., KimJ.W.. Chronic hepatitis B, non-Hodgkin's lymphoma, and effect of prophylactic antiviral therapy.J Clin Virol.2011; 51(4): 241–245.
88.
HsuC., HsiungC.A., SuI.J.. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.Hepatology.2008; 47(3): 844–853.
89.
SimpsonN.D., SimpsonP.W., AhmedA.M.. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.J Clin Gastroenterol.2003; 37(1): 68–71.
90.
ZiakasP.D., KarsaliakosP., MylonakisE.. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance.Haematologica.2009; 94(7): 998–1005.
91.
HuangY.H., HsiaoL.T., HongY.C.. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.J Clin Oncol.2013; 31(22): 2765–2772.
92.
HuangH., LiX., ZhuJ.. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.JAMA.2014; 312(23): 2521–2530.
